Barclays Reiterates a Buy Rating on Relay Therapeutics (RLAY)

Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the best biotech penny stocks to buy right now. In a report released on July 29, Peter Lawson from Barclays maintained a Buy rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) with a price target of $17.00.

Relay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will Triple

A chemist arranging containers of compounds, ready for the commercialization process.

Relay Therapeutics, Inc. (NASDAQ:RLAY) reported in its fiscal Q1 2025 earnings that it implemented strategic cost reductions to extend operating runway into 2029. The reductions are also aimed at funding key objectives for the company.

These objectives include the “execution of RLY-2608 Phase 1 vascular malformations trial through clinical proof-of-concept data”, advancement of Fabry and NRAS program to Investigational New Drug application (IND) readiness, advancement of one research-stage program, and more.

Relay Therapeutics, Inc. (NASDAQ:RLAY) is a clinical-stage precision medicine company that uses advanced computational and experimental technologies to innovate drug discovery.

Its primary focus is on genetic disease indications and targeted oncology. The company’s Dynamo platform integrates a range of cutting-edge experimental and computational approaches to understand protein structure and motion in drug discovery.

While we acknowledge the potential of RLAY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RLAY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.